Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

R. Peinò, J. Fernández Alvarez, A. Peñalva, Robert Considine, S. Rodriguez-Segade, J. Rodriguez-Garcia, F. Cordido, F. F. Casanueva, C. Dieguez

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Leptin, the product of the ob gene, is a recently discovered hormone secreted by adipocytes. Serum leptin concentrations increase in correlation with the percentage of body fat, but besides that little is known about the physiological actions of leptin in humans. The aim of this study was to assess the influence of changes in circulating free-fatty acids on serum leptin levels. Increases in plasma FFA levels (p < 0.02) were obtained in a group of normal subjects following the administration of intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin). FFA reduction was achieved through the administration of acipimox (250 mg, orally, at 0 min and at 210 min), a lipid-lowering drug devoid of side effects, to a group of normal (p < 0.02) and obese subjects (p < 0.05). An increase in circulating FFA levels in normal subjects (n = 6), following administration of a lipid-heparin infusion, failed to modify plasma leptin levels as assessed by the area under the curve (AUC; mean ± SE 892 ± 168 for placebo vs 896 ± 260 following intralipid plus heparin). Similarly, whereas acipimox pretreatment induced a reduction in FFA levels compared to placebo in normal (n = 6) and obese subjects (n = 8), it also failed to modify plasma leptin levels at any time-point studied. The results indicate that short-term reduction or increase in circulating FFA are not associated to changes in plasma leptin levels.

Original languageEnglish
Pages (from-to)526-530
Number of pages5
JournalJournal of Endocrinological Investigation
Volume21
Issue number8
StatePublished - Sep 1998

Fingerprint

Leptin
Nonesterified Fatty Acids
Serum
Heparin
Area Under Curve
Placebos
Lipids
Drug-Related Side Effects and Adverse Reactions
Adipocytes
Adipose Tissue
Hormones
phospholipid emulsion soybean oil

Keywords

  • Free-fatty acids
  • Leptin
  • Obesity

ASJC Scopus subject areas

  • Endocrinology

Cite this

Peinò, R., Fernández Alvarez, J., Peñalva, A., Considine, R., Rodriguez-Segade, S., Rodriguez-Garcia, J., ... Dieguez, C. (1998). Acute changes in free-fatty acids (FFA) do not alter serum leptin levels. Journal of Endocrinological Investigation, 21(8), 526-530.

Acute changes in free-fatty acids (FFA) do not alter serum leptin levels. / Peinò, R.; Fernández Alvarez, J.; Peñalva, A.; Considine, Robert; Rodriguez-Segade, S.; Rodriguez-Garcia, J.; Cordido, F.; Casanueva, F. F.; Dieguez, C.

In: Journal of Endocrinological Investigation, Vol. 21, No. 8, 09.1998, p. 526-530.

Research output: Contribution to journalArticle

Peinò, R, Fernández Alvarez, J, Peñalva, A, Considine, R, Rodriguez-Segade, S, Rodriguez-Garcia, J, Cordido, F, Casanueva, FF & Dieguez, C 1998, 'Acute changes in free-fatty acids (FFA) do not alter serum leptin levels', Journal of Endocrinological Investigation, vol. 21, no. 8, pp. 526-530.
Peinò R, Fernández Alvarez J, Peñalva A, Considine R, Rodriguez-Segade S, Rodriguez-Garcia J et al. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels. Journal of Endocrinological Investigation. 1998 Sep;21(8):526-530.
Peinò, R. ; Fernández Alvarez, J. ; Peñalva, A. ; Considine, Robert ; Rodriguez-Segade, S. ; Rodriguez-Garcia, J. ; Cordido, F. ; Casanueva, F. F. ; Dieguez, C. / Acute changes in free-fatty acids (FFA) do not alter serum leptin levels. In: Journal of Endocrinological Investigation. 1998 ; Vol. 21, No. 8. pp. 526-530.
@article{877d5bb834bc4f32ad03222ececd41c3,
title = "Acute changes in free-fatty acids (FFA) do not alter serum leptin levels",
abstract = "Leptin, the product of the ob gene, is a recently discovered hormone secreted by adipocytes. Serum leptin concentrations increase in correlation with the percentage of body fat, but besides that little is known about the physiological actions of leptin in humans. The aim of this study was to assess the influence of changes in circulating free-fatty acids on serum leptin levels. Increases in plasma FFA levels (p < 0.02) were obtained in a group of normal subjects following the administration of intralipid plus heparin (250 ml 10{\%} Intralipid plus 5000 U heparin). FFA reduction was achieved through the administration of acipimox (250 mg, orally, at 0 min and at 210 min), a lipid-lowering drug devoid of side effects, to a group of normal (p < 0.02) and obese subjects (p < 0.05). An increase in circulating FFA levels in normal subjects (n = 6), following administration of a lipid-heparin infusion, failed to modify plasma leptin levels as assessed by the area under the curve (AUC; mean ± SE 892 ± 168 for placebo vs 896 ± 260 following intralipid plus heparin). Similarly, whereas acipimox pretreatment induced a reduction in FFA levels compared to placebo in normal (n = 6) and obese subjects (n = 8), it also failed to modify plasma leptin levels at any time-point studied. The results indicate that short-term reduction or increase in circulating FFA are not associated to changes in plasma leptin levels.",
keywords = "Free-fatty acids, Leptin, Obesity",
author = "R. Pein{\`o} and {Fern{\'a}ndez Alvarez}, J. and A. Pe{\~n}alva and Robert Considine and S. Rodriguez-Segade and J. Rodriguez-Garcia and F. Cordido and Casanueva, {F. F.} and C. Dieguez",
year = "1998",
month = "9",
language = "English",
volume = "21",
pages = "526--530",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "8",

}

TY - JOUR

T1 - Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

AU - Peinò, R.

AU - Fernández Alvarez, J.

AU - Peñalva, A.

AU - Considine, Robert

AU - Rodriguez-Segade, S.

AU - Rodriguez-Garcia, J.

AU - Cordido, F.

AU - Casanueva, F. F.

AU - Dieguez, C.

PY - 1998/9

Y1 - 1998/9

N2 - Leptin, the product of the ob gene, is a recently discovered hormone secreted by adipocytes. Serum leptin concentrations increase in correlation with the percentage of body fat, but besides that little is known about the physiological actions of leptin in humans. The aim of this study was to assess the influence of changes in circulating free-fatty acids on serum leptin levels. Increases in plasma FFA levels (p < 0.02) were obtained in a group of normal subjects following the administration of intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin). FFA reduction was achieved through the administration of acipimox (250 mg, orally, at 0 min and at 210 min), a lipid-lowering drug devoid of side effects, to a group of normal (p < 0.02) and obese subjects (p < 0.05). An increase in circulating FFA levels in normal subjects (n = 6), following administration of a lipid-heparin infusion, failed to modify plasma leptin levels as assessed by the area under the curve (AUC; mean ± SE 892 ± 168 for placebo vs 896 ± 260 following intralipid plus heparin). Similarly, whereas acipimox pretreatment induced a reduction in FFA levels compared to placebo in normal (n = 6) and obese subjects (n = 8), it also failed to modify plasma leptin levels at any time-point studied. The results indicate that short-term reduction or increase in circulating FFA are not associated to changes in plasma leptin levels.

AB - Leptin, the product of the ob gene, is a recently discovered hormone secreted by adipocytes. Serum leptin concentrations increase in correlation with the percentage of body fat, but besides that little is known about the physiological actions of leptin in humans. The aim of this study was to assess the influence of changes in circulating free-fatty acids on serum leptin levels. Increases in plasma FFA levels (p < 0.02) were obtained in a group of normal subjects following the administration of intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin). FFA reduction was achieved through the administration of acipimox (250 mg, orally, at 0 min and at 210 min), a lipid-lowering drug devoid of side effects, to a group of normal (p < 0.02) and obese subjects (p < 0.05). An increase in circulating FFA levels in normal subjects (n = 6), following administration of a lipid-heparin infusion, failed to modify plasma leptin levels as assessed by the area under the curve (AUC; mean ± SE 892 ± 168 for placebo vs 896 ± 260 following intralipid plus heparin). Similarly, whereas acipimox pretreatment induced a reduction in FFA levels compared to placebo in normal (n = 6) and obese subjects (n = 8), it also failed to modify plasma leptin levels at any time-point studied. The results indicate that short-term reduction or increase in circulating FFA are not associated to changes in plasma leptin levels.

KW - Free-fatty acids

KW - Leptin

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=0031706028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031706028&partnerID=8YFLogxK

M3 - Article

C2 - 9801994

AN - SCOPUS:0031706028

VL - 21

SP - 526

EP - 530

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 8

ER -